Although embryonic stem (ES) cells have been induced to differentiate into diverse neuronal cell types, the production of cortical projection neurons with the correct morphology and axonal connectivity has not been demonstrated.
Here, we show that in vitro patterning is critical for generating neural precursor cells (ES-NPCs) competent to form cortical pyramidal neurons.
Image via Wikipedia
A research group at Imperial College London has designed a new treatment able to significantly improve the body’s capacity to repair damage caused by a heart attack or bone fracture. The new therapy, described in Cell Stem Cell, ‘fools’ the spinal cord inducing it to ’overproduce’ stem cells which repair damaged tissues in the body. Researchers hope to test the treatment on animals by the end of the year. If testing is successful, the next step will be to experiment on human beings attempting to induce them to use their own stem cells
Scientific inspiration can come from anywhere — a person, an event, even an experiment gone awry. But perhaps nothing can drive innovation more powerfully than the passion born of tragedy. Or, in Douglas Melton’s case, near tragedy. The co-director of the Harvard Stem Cell Institute (HSCI) is one of the leading figures in the search for cures for presently incurable diseases, and his breakthrough work is challenging many long-held beliefs about the ways biology and human development work.
But it was a very personal experience that brought Melton to stem cells, one that 17 years later he still finds difficult
Neuralstem Inc. has received the green light to begin the first human stem cell trial to treat Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig’s disease. The company’s stock soared on the news.
Neuralstem has only received approval for the first stage of the trial that would consist of 12 patients who will receive stem cell injections in the lumbar area of the spinal cord.
Neuralstem said the trial will be under the direction of principal investigator Dr. Eva L. Feldman, Director of the University of Michigan Health System ALS Clinic and the Program for Neurology Research & Discovery.
Emory University researchers are participating in a groundbreaking clinical trial to treat patients with amyotrophic lateral sclerosis (ALS) using human neural stem cells.
The Phase 1 trial, will assess the safety of stem cells, and the surgical procedures and devices required, for multiple injections of the cells directly into the spinal cord.
“This is the first U.S. clinical trial of stem cell injections into the spinal cord for the treatment of ALS,” says principal researcher Jonathan Glass, professor of neurology in the School of Medicin, and director of the Emory ALS Center. “Our main goal in this early phase is to